| 抗体药物偶联物在复发难治性弥漫大B细胞淋巴瘤中的应用进展 |
| |
| 引用本文： | 车瑀,张倩雯,马晔,葛晓燕.抗体药物偶联物在复发难治性弥漫大B细胞淋巴瘤中的应用进展[J].实用药物与临床,2022(2):177-182. |
| |
| 作者姓名： | 车瑀 张倩雯 马晔 葛晓燕 |
| |
| 作者单位： | 山西医科大学第二临床医学院;山西医科大学第二医院血液内科 |
| |
| 摘 要： | 弥漫大B细胞淋巴瘤(DLBCL)患者在接受R-CHOP标准方案治疗后,仍有一部分患者症状复发或难治,预后很差。抗体药物偶联物对肿瘤发挥高效杀伤作用的同时,不损伤正常组织及细胞,成为不可或缺的治疗策略。多种药物已通过严格的临床试验并表现出良好的有效性及可控范围内的安全性,临床试验的开展也为抗体药物偶联物的下一步发展指明了方向。
|
| 关 键 词： | 弥漫性大B-细胞淋巴瘤 单克隆抗体 抗体药物偶联物 分子靶向治疗 |
Progress in application of antibody-drug conjugates in the treatment of relapsed refractory DLBCL |
| |
| CHE Yu,ZHANG Qian-wen,MA Ye,GE Xiao-yan.Progress in application of antibody-drug conjugates in the treatment of relapsed refractory DLBCL[J].Practical Pharmacy and Clinical Remedies,2022(2):177-182. |
| |
| Authors: | CHE Yu ZHANG Qian-wen MA Ye GE Xiao-yan |
| |
| Institution: | (Second Clinical Medical College of Shanxi Medical University,Taiyuan 030001,China;Department of Hematology,the Second Hospital of Shanxi Medical University,Taiyuan 030001,China) |
| |
| Abstract: | After the standard treatment of R-CHOP regimen, some patients with diffuse large B-cell lymphoma still have relapse or refractory disease, and the prognosis of them is poor.Antibody-drug conjugates can effectively kill tumors while avoiding damage to normal tissues and cells, becoming an indispensable treatment strategy at the moment.Many drugs have passed rigorous clinical trials and have shown good efficacy and controlled safety, and the development of clinical trials also indicates the direction for the future development of antibody-drug conjugates. |
| |
| Keywords: | Diffuse large B-cell lymphoma Monoclonal antibody Antibody-drug conjugate Molecular targeted therapy |
| 本文献已被 维普 等数据库收录！ |
